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SUMMARY 
Thalassemia is one of the most common genetic disorders in Egypt. With the total population 
of 70 million, there are approximately 600,000 affected individuals and more than 20 million 
thalassemia carriers.  Thalassemia is therefore one of the major health problems in Egypt.  
B-Thalassemias are priority genetic diseases for prevention programs. Rapid genotype 
characterization is fundamental in the diagnostic laboratory, especially when offering 
prenatal diagnosis for carrier couples. Introduction of the real time PCR has made a 
revolution in the time taken for the PCR reactions. We present a method for the diagnosis of 
the common mutations of the B-thalassemia in Egyptian children & families. The procedure 
depends on the real-time PCR using specific fluorescently labeled hybridization probes. The 
melting temperature for each of the specific probes obtained after the PCR reaction permits 
the identification of the specific mutation. Genotyping of 20 thalassemic children attending 
the hematology clinic of the children specialized hospital and 10 controls was done using 
Real-time PCR and the conventional Amplification Refractory Mutation System (ARMS) 
technique. Analysis revealed identical results to most of the patients and they were further 
checked by the sequencing results of the DNA samples. The established method is a robust, 
fast and straight forward assay that allows the detection of the common B-thalassemia 
mutations in Egypt. The described LightCycler system protocol can rapidly screen for many 
B-globin gene mutations. 
 
[Afr J Health Sci. 2006; 13: 70-77]
 
Introduction 
Formerly the distribution of thalassemia had been 
mainly limited to the areas from the Mediterranean 
across the Middle East through Southern Asia to 
Southeast Asia in the so called ‘thalassemia belt [1] 
However, recent migrations of people have spread 
thalassemia genes throughout the world. 
Furthermore, there has been a major transition in the 
demography of common illnesses over the past years. 
[2] This change includes a remarkable decline in 
childhood mortality due to infections and 
malnutrition in some regions. As a result, many 
infants with serious genetic disorders such as 
thalassemia can now survive the early months of life 
and live long enough to require treatment for their 
hematologic disorders. Given the demographic 
population shifts, thalassemia is at present 
considered to be a global health problem. [2] 
In spite of the more than 170 different B-
thalassaemia mutations described around the world 
(http://globin.cse.psu.edu/globinlhtml/huismanltha





more than 80% of the thalassaemic alleles detected in 
the different geographic areas with a high prevalence  
of B-thalassaemia. [5] Thus, in the countries 
bordering the Mediterranean basin, the major 
mutations of the B-globin gene are CD-39 (C62434T) 
and IVS 1-110 (G62388A) [6]. The IVS 1-6 
(T62284C) mutation is also relatively frequent, and, 
in Egypt, the mutations IVS I-I (G62279A), CD-37 
(G62429A) and CD-6 (-A62206) are also observed 
[7]. 
The ability to perform rapid DNA analysis for 
genotype characterization has become an increasingly 
important requirement for the clinical diagnostic 
laboratory. Currently, a wide variety of methods exist 
for detecting point mutations in a DNA molecule. 
Classic methods include oligonucleotide 
hybridization, endonuclease restriction analysis of 
PCR products, the Amplification Refractory 
Mutation System (ARMS), denaturing gradient gel 
electrophoresis, and direct sequencing. All of the 
above methods require several hours, and sometimes 
days, for complete    diagnosis  extensive  processing, 
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and some of them use radiolabelled oligonucleotides 
with potential contamination issues and problems 
with disposal of radioactive waste [8]. Consequently, 
there is a need for more rapid, high-throughput 
assays. Recently, systems have been developed that 
integrate microvolume rapid-cycle PCR with 
fluorometry, offering real-time fluorescent 
monitoring of the amplification reaction for 
quantitative PCR and/or characterization of PCR 
products for rapid genotyping without the need for 
post-PCR sample manipulation [1,2]. The 
LightCyclerTM (Roche Molecular Biochemicals) is 
one such system. The detection of potential sequence 
differences (usually single-nucleotide 
polymorphisms) for genotyping applications involves 
the use of two fluorescently labeled probes that 
hybridize to adjacent internal sequences within target 
amplified DNA, one of which covers the region 
expected to contain the mutation(s). Close proximity 
of annealed probes facilitates fluorescence resonance 
energy transfer between them. Probes are designed to 
have different melting temperatures (Tms), such that 
the probe with the lower Tm lies over the mutation 
site(s). Monitoring of the emitted fluorescent signals 
as the temperature increases detects loss of 
fluorescence as the probe with the lower Tm melts off 
the template. A single base mismatch under this 
probe produces a Tm shift of 5–10 °C, allowing easy 
distinction between wild-type and mutant alleles. The 
ability to detect base mismatches under the probe 
with the lower Tm (mutation detection probe) and the 
use of two, different-colored probes allows more than 
one mutation to be screened in a single PCR reaction. 
Because of its low costs, reproducibility, and ease of 
handling, the assay is potentially suited for the 
routine clinical laboratory. [9] In this study we aimed 
to report the standardization of a real-time detection 
method for the common B-thalassemia mutations in 
Egypt. 
 
Materials and Methods 
Provisional diagnosis of thalassemia syndromes was 
made based on characteristic clinical manifestations 
and morphologic red cell abnormalties. Definite 
diagnosis was confirmed by hemoglobin typing based 
on the electrophoretic or chromatographic separation 
of Hb from the blood. Iron deficiency anemia was 
first excluded before making the diagnosis of 
thalassemia because it may complicate the diagnosis. 
[10] 
 
Subject: The study included genomic DNA from 30 
patients; 20 thalassemics attending the hematology 
clinic of Abulrish hospital and 10 non-thalassemic 
subjects. These individuals had been previously 
tested for the major β-thalassemia mutations (IVS I-
1, IVS I-6, IVS I-110) using the conventional ARMS 
method [11] and their diagnosis was confirmed by 
sequencing. 
 
Amplification Refractory Mutation System (ARMS): 
ARMS primers were designed to detect normal and 
mutant DNA. The nucleotide at 3' end of the mutant 
primer was complementary to the change of DNA 
sequence caused by mutation that was being looked 
for. A set of internal control primers were included in 
each assay, to demonstrate the efficacy of the PCR. 
They amplify a region of DNA a short distance from 
that amplified by the ARMS primers and produce a 
861 bp fragment. Oligonucleotide primers to detect 
the 3 mutations selected for this study were 
synthesized according to the following sequence  
 
 
I-Allele specific primers: 
IVS1-110      Mutant               5'ACC AGC AGC CTA AGG GTG GGA AAA TAG ACT 
                      Normal               5'ACC AGC AGC CTA AGG GTG GGA AAA TAG ACC 
 
IVS1-6         Mutant                 5'TCT CCT TAA ACC TGT CTT GTA ACC TTC ATG 
                     Normal                5'TCT CCT  TAA ACC TGT CTT GTA ACC TTC ATA 
 
IVS1-1        Mutant                 5'TTA AAC CTG TCT TGT AAC CTT GAT ACG AAT 
                    Normal                5'TTA AAC CTG TCT TGT AAC CTT GAT ACG AAC 
 
II-Common primer:                 5'ACC TCA CCC TGT GGA GCC AC 
 
III-Internal  control primer: 
        Control A: 5'CAA TGT ATC ATG CCT CTT TGC ACC 
        Control B: 5'GAG TCA AGG CTG AGA GAT GCA GGA 
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PCR reaction mix  
5 µmol/L of each ARMS primers and  Taq enzyme, 
3mM Mgcl2, 400 µM of dNTPs and DNA samples 
were used in a final volume of 25 µl under the 
following cycling conditions: Initial precycling 
denaturation hold at 94°C for 5 min. Then 25 cycles 
of denaturation at 93°C for 1 min, annealing at 65°C 
for 1 min, extension at 72°C for 15 min. In the last 
cycle, extension was prolonged for 5 min. The 
products were then run on 2% agarose gel using gel 
electrophoresis and visualized on UV 
transilluminator to detect the presence or absence of 
the mutant allele. 
 
Mutation detection using specific fluorescently 
labelled hybridisation probes 
The method was carried out on the LightCycler 
(Roche Diagnostics, Mannheim, Germany), and 
comprised real-time PCR amplification of a β-globin 
gene fragment of 609 bp using the GLO F and GLO 
R primers together with a pair of hybridisation 
probes. One of the probes, the anchor probe, was 
located in the vicinity of the mutation and was 
labelled in its 5' end with Red 705. An adjacent 
sensor probe, was placed over the mutation 2 to 5 
nucleotides apart from the anchor probe, and was 
labelled with fluorescein at its 3' end. 
Design of primers and probes. 
Primers and probes were all designed and synthesized by TIB MOLBIOL (Berlin, Germany) 
GLOF: 5'GAAGAGCCAAGGACAGGTAC 
GLOR: 5'ACTGAGTGAGCTGCACTGTGA 
IVS I-1/6 Sensor: TGTAACCTTGATACCAACCTGCCCA-Fluorescein (mutations underlined) 
IVS I-1/6 Anchor: LCRed 705-CCTCACCACCAACTTCA TCCACGTTCACC-Phosphate 
IVS I-110 Sensor: GACTCTCTCTGCCTATTAGTCTATTTTCCC-Fluorescein (mutation underlined) 
IVS I-110 Anchor: LCRed 705-CCTT AGGCTGCTGGTGGTCT ACCCTTG-Phosphate 
 
 
Real-time PCR protocol 
PCR was performed in capillary tubes in 10 µl final 
volume using 1µl of DNA template (50-100 ng), 1x 
FastStart LightCycler™-DNA Master Hybridization 
Probes (Roche Molecular Biochemicals), 0.3 µM of 
each primer and 4 mM MgCl. The hybridisation 
probes were used at 0.2µM, with the exception of the 
IVS 1-1/6 sensor probe, which was used at 0.1 µM. 
The PCR program involved incubation at 94°C for 10 
min. Amplification comprised 45 cycles of 
denaturation at 94°C for 10 seconds, annealing at 
55°C for 10 seconds, and elongation at 72°C for 25 
seconds. The mutation detection was achieved by 
melting curve profiles. The program consisted of an 
initial denaturation at 95°C for 30 seconds, followed 
by an annealing at 40°C for 30 seconds to permit the 
hybridisation of the probes. In the case of the probes 
for IVS I-1/6, the decrease of temperature was 
gradual with incubations of 25 seconds at 71°C and 
66°C (Tm of the anchor and sensor probes, 
respectively). Then, the temperature was increased at 
a rate of 0.1°C/second up to 90°C with continuous 
fluorescence monitoring. The software provided with 
the equipment (LightCycler 2) gives the temperature 
of melting (Tm) of the sensor probe. A base pair 
mismatch between the sensor probe and template 
causes a decrease in Tm that can be easily detected 




The Light Cycler method was standardized by 
analyzing DNA from 10 normal controls not 
suffering from any kind of anemia. The melting 
curves for the IVS I-1/6 probes, yielded a Tm mean ± 
standard deviation of 65.96 ±0.41° C while for the 
IVS I-110 yielded a Tm mean ± standard deviation of 
62.67 ±0.32° C for the 10 normal samples. Each PCR 
reaction included heterozygous and homozygous 
(when available) samples for the mutation under 
evaluation, five controls negative for the mutation, 
and a DNA-free blank to monitor the absence of 
contamination. In all sets of experiments for each 
mutation, the melting curves with the detection probe 
distinguished the wild-type from mutant alleles, 
allowing assignment of wild-type, heterozygous, or 
homozygous status to each sample as expected. No 
false-positive or false-negative results or 
contamination was observed in any case.  
 
The frequency of mutation distribution in the 20 
thalassemic patients is illustrated in Fig (1). The most 
frequently encountered mutated allele was the IVS I-
110; 7 (35 %) patients were heterozygous for IVS I-
110 while only one was homozygous. Four (20%) 
were double heterozygous for IVS I-110 and IVS I-6 
while one patient was double heterozygous for IVS I-
110 and IVS I-1. Two patients were heterozygous for 
IVS I-1 while one patient only was heterozygous for 
IVS I-6.  The homozygous groups; IVS I-1, IVS I-6 
and IVS I-110 constituted of one patient in each 
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group. In two samples, we observed different melting 
curves which were close to but distinct from the 
mutant curves of the detection probes; after 
sequencing, these samples were found to have the 
IVS I-5 and the frame shift mutations, which are less 
common in the Egyptian population. All genotype 
results were confirmed by routine methodologies, 
including denaturing gradient gel electrophoresis in 
combination with ARMS PCR and direct sequencing 
[3,11,12] 
 
                      Fig.1









Homo IVSI-110 Homo IVSI-6 Homo IVSI-1
Hetero IVSI-110 Hetero IVSI-6 Hetero IVSI-1




The IVS I-1 mutation gave a Tm mean ± standard 
deviation of 59.07 ± 0.45° C, the IVS I-6 mutation 
gave a Tm mean ± standard deviation of 61.34 ± 
0.27° C while IVS I-110 mutation gave Tm mean ± 
standard deviation of 66.96 ± 0.58° C.  Here the 
design of the sensor probes of the IVS 1-1/6 and IVS 
I-110 takes the advantage of the fact that different 
mutations placed along the sequence produce distinct 
effects on the Tm [12] Thus, the melting curves 
permitted the distinction of the normal allele from 
IVS 1-1 and IVS 1-6 mutations separated by five 
nucleotides apart. The melting curves obtained 
immediately after the amplification procedure 
permitted the identification of the Tm peaks 
corresponding to normal or mutated alleles in each 
sample (fig 2A) 
 
Detection of IVS I-I and IVS 1-6 mutants with 
IVS I-1/6 probes 
Normal and IVS I-6 homozygous (HO) subjects show 
only one peak corresponding to normal (65.96°C)  
 
 
and mutated allele (61.34 °C), respectively, while 
IVS 1-6 heterozygous (HE) patient shows both 
normal and mutated peaks (fig  2 C). The IVS I -1 HE 
patient shows a mutated peak 2°C below (59.07 0c) 
that of the IVS 1-6 mutation (fig2B).  
 
Detection of IVS 1-110 mutation 
The normal subject showed one peak at 62.67 °C. 
The IVS 1-110 HE patient showed the peak of the 
normal and the mutated allele (66.96°C). While HO 
showed one peak of the mutated allele (Fig 3) Thus 
the Melting curves in an 18 thalassemic patients 
indicated homozygosity & heterozygosity for a 
mutation within the B-globin gene regions covered 
by the mutation detection probes. On the other hand, 
we noticed that some mutations, including IVSI-5 
and the frame shift mutations had different melting 
curves, which were distinct from the wild type and 
the mutated type of both probes. In such cases, the 
mutations were identified by use of ARMS and by 
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The B-globin gene is a relatively small gene (2000 
bp) located in the short arm of chromosome 11. [15] 
Although 180 causative mutations have been reported 
for B-thalassemia syndromes, the spectrum of 
mutations and their frequencies in most populations 
usually consist of a limited number of common 
mutations and a slightly larger number of rare 
mutation [16].  With the aim of rapid DNA analysis, 
real-time PCR has become an important tool in both 
research and routine clinical diagnostics [1, 2, 17, 18] 
Use of the LightCycler facilitates, and allows 
simultaneous multiple mutation detection through the 
flexible design of detection probes.  
Twenty sequenced DNA samples with B-
thalassemia mutations and 10 controls (with normal 
B-globin gene) were included in the study. Rapid 
Screening of B-Globin Gene by Real-Time PCR was 
considered an appropriate model for developing the 
described protocol. In the selected samples most of 
the Egyptian common mutations were found 
represented with different forms; IVS I-110 
homozygous and heterozygous, IVS I-1 homozygous 
and heterozygous, IVS I-6 homozygous and 
heterozygous together with double heterozygous 
mutations of IVS I-110 with IVS I-1 and IVS I-6. We 
designed a duplicate reaction protocol to screen for 
the multiple B-globin gene mutations, with the use of 
four probes, two sensor mutation probes located over 
the mutated areas and two anchor probes located in 
the vicinity of the mutated area over a normal B-
globin region. Using detection probes complementary  
to the wild-type sequence allowed the identification 
of mutations by an abnormal melting temperature of   
 
 
the probe even if the type of mutation is unknown. 
This potentially allowed the distinction of any allele 
with a mutation under the length of the probe, 
minimizing the costs and time required to screen a 
spectrum of mutations, as is necessary for most 
populations in which B-thalassemia is common. This 
approach was greatly facilitated by the close 
proximity of many B-thalassemia mutations within 
the B-globin gene [19]. 
All results were in complete concordance with 
the genotypes obtained in parallel by routine 
methodologies; ARMS and sequencing [8]. Normal 
controls were identified as wild-types, 7 patients were 
heterozygous for IVS I-110, 2 patients were 
heterozygotes for IVS I-1 and one for IVS I-6. One 
patient was homozygous for each of the previously 
mentioned mutations. Six patients had double 
heterozygous mutations; 4 for IVS I-110 and IVS I-6 
and 2 for the IVS I-110 and IVS I-1. Two patients 
had Tm that was completely different from the 
mutations detected previously, one had IVS I-5 (Tm 
53°C) and the other was a frame shift mutation (Tm 
50.2°C). The genotype results obtained with the 
LightCycler protocol were completed within a single 
working day, whereas those obtained with routine 
methods required 2–3 days. 
This method demonstrated 100% reliability in 
distinguishing wild-type versus mutant alleles. The 
application of the protocol to screen samples with 
unknown mutations that have been sequenced 
allowed the evaluation of the method and highlighted 
several points. The first point is that all samples with 
mutations within the gene regions covered by the 
LightCycler detection probes were positively 
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detected as having a variant allele, which allowed all 
mutations to be distinguished reliably from wild-type 
alleles. The second point is that mutations with shifts 
(e.g. frame shift mutation) or other mutations (e.g. 
IVS I-5) produced a Tm that was near from the other 
mutations but distinct from the wild type, thus the 
identification of a single sample with a B-thalassemia 
mutation that is uknown indicates that the system can 
also detect rare or novel mutations so long they lie 
within the detection sequence of the probes. [20] 
The identity of results obtained with the newly 
established method and with our conventional ARMS 
method in the group of patients, and lack of false 
positive in the non-thalassemics, clearly confirms the 
equivalence of the methods for the mutations studied. 
However, real time method has the advantage of 
being considerably less time-consuming than ARMS 
and other conventional methods as sequencing. 
Thus the major advantage of the proposed 
method is its simplicity, swiftness and reliability, 
characteristics that make this method suitable not 
only for diagnosis but also for epidemiological 
surveys, which require the analysis of a considerable 
number of samples. Mutation characterization in 
carriers is a prerequisite when offering prenatal 
diagnosis to couples at risk for having an affected 
child and frequently needs to be achieved as quickly 
as possible, especially when at-risk couples present 
after establishment of a pregnancy. [21] 
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